Tag: NTLA

3 Biotechs With Promising Gene Therapies in the Spotlight

Recently, bluebird bio, Inc. BLUE obtained FDA approval for its third gene therapy, lovotibeglogene autotemcel (lovo-cel), for the treatment of sickle cell disease (“SCD”) in patients aged 12 and older who have a history of vaso-occlusive events (“VOEs”). The FDA approved lovo-cel under the brand name Lyfgenia. Concurrently, it also…

Continue Reading 3 Biotechs With Promising Gene Therapies in the Spotlight

Could Intellia Therapeutics Become the Next CRISPR Therapeutics?

Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) have one big thing in common: They both specialize in the hot area of gene editing, or the repairing of faulty genes responsible for disease. But CRISPR Therapeutics is farther along on the path to commercialization, recently scoring its first product…

Continue Reading Could Intellia Therapeutics Become the Next CRISPR Therapeutics?

CRISPR Therapies Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, and Treatment Outlook

PRESS RELEASE Published December 12, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, CRISPR Therapies pipeline constitutes 25+ key companies continuously working towards developing 30+ CRISPR Therapies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The CRISPR Therapies…

Continue Reading CRISPR Therapies Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, and Treatment Outlook

You Don’t Have to Pick a Winner in Gene-Editing. Do This Instead.

The pace of innovation in biotechnology is accelerating at a rapid clip. It took researchers 13 years to sequence the first full human genome. By contrast, it only took CRISPR Therapeutics (CRSP 4.57%) 10 years to bring their “molecular scissors” concept to market. With machine learning and artificial intelligence in…

Continue Reading You Don’t Have to Pick a Winner in Gene-Editing. Do This Instead.

Crispr and Cas Gene Market to Hit $6.47 Billion by 2030: Coherent Market Insights (CMI)

CMI Crispr and Cas gene are segment of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas) that act as an acquired immune system in bacteria and archaea defend against foreign genetic elements such as viruses. These genes are majorly used for genome editing applications in various industries…

Continue Reading Crispr and Cas Gene Market to Hit $6.47 Billion by 2030: Coherent Market Insights (CMI)

The 6 Biggest Stories in Medicine in 2023

It’s so hard to avoid spoilers online. Take, for example, right now. Welcome back to our 7th edition of This Year in Medicine, our annual end-of-year recap series that highlights the greatest stories, challenges, moments and innovations in health care. On every Monday, Wednesday and Friday this December, our team…

Continue Reading The 6 Biggest Stories in Medicine in 2023

CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big

Natali_Mis Gene editing, also known as genome editing, is a method where the DNA of an organism is modified using biotechnological techniques. It allows scientists to add, remove, or alter genetic material at particular locations in the genome. This 2-part series will cover the basics of CRISPR-Cas9 (see below) in…

Continue Reading CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big

The UK becomes the first country to approve CRISPR treatment

Today, the United Kingdom became the first country to give regulatory approval to a medical procedure that uses CRISPR gene editing. The Medicines and Healthcare products Regulatory Agency (MHRA) approved Casgevy, a therapy that will be used to treat sickle cell disease and beta thalassemia (also called β -thalassaemia).  [Related:…

Continue Reading The UK becomes the first country to approve CRISPR treatment

How Will the Market React to Intellia Therapeutics Inc (NTLA) Stock Getting a Bearish Rating

News Home Tuesday, November 14, 2023 10:04 AM | InvestorsObserver Analysts Mentioned in this article The market has been down on Intellia Therapeutics Inc (NTLA) stock recently. NTLA gets a Bearish score from InvestorsObserver Stock Sentiment Indicator. Intellia Therapeutics Inc has a Bearish sentiment reading. Find out what this means…

Continue Reading How Will the Market React to Intellia Therapeutics Inc (NTLA) Stock Getting a Bearish Rating

Intellia Therapeutics Receives European Union Orphan Drug

CAMBRIDGE, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative single-dose therapeutics leveraging CRISPR-based technologies, today announced that the European Commission (EC) has granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002…

Continue Reading Intellia Therapeutics Receives European Union Orphan Drug

Gene editing therapy leads to sustained drop in toxic TTR protein

A single infusion of NTLA-2001, an experimental gene editing therapy, generally is safe and leads to a marked reduction in blood levels of the harmful transthyretin (TTR) protein in people with familial amyloid polyneuropathy (FAP) and ATTR amyloidosis with cardiomyopathy (ATTR-CM). These updated, interim data cover 65 of 72 patients…

Continue Reading Gene editing therapy leads to sustained drop in toxic TTR protein

Intellia Presents New Interim Data from the Ongoing Phase 1

Updated data from over 60 patients showed consistent, deep and durable serum TTR reduction achieved with a single dose of NTLA-2001, including in 29 patients who have now reached 12 months or more of follow-up NTLA-2001 was generally well-tolerated across both polyneuropathy and cardiomyopathy arms at all dose levels tested…

Continue Reading Intellia Presents New Interim Data from the Ongoing Phase 1

Top 20 Genomics Companies in the World

In this piece, we will take a look at the top 20 genomics companies in the world. If you want to skip our analysis of the genomics industry, then take a look at the Top 5 Genomics Companies in the World. Modern day science has delivered a plethora of advancements…

Continue Reading Top 20 Genomics Companies in the World

How CRISPR Companies Target Sickle Cell Anemia

A Crippling And Painful Disease Sickle Cell Disease (SCD) is a blood disease caused by a genetic mutation. This mutation creates abnormal hemoglobin, the protein carrying oxygen in the blood’s red cells. As a result, red cells are shaped like sickles and tend to get stuck in blood vessels, causing…

Continue Reading How CRISPR Companies Target Sickle Cell Anemia

Phase 3 trial of NTLA-2001 for ATTR-CM to launch by year’s end

Intellia Therapeutics is launching a pivotal Phase 3 clinical trial in the U.S. to evaluate the safety and effectiveness of its investigational gene-editing therapy NTLA-2001 in people with ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study, which is expected to start by the end of the year, follows the recent approval…

Continue Reading Phase 3 trial of NTLA-2001 for ATTR-CM to launch by year’s end

Gene Editing Market to Be Valued USD 36.4 Billion by 2032, North America in the Lead

Marketresearch.biz highlights that the growth of gene editing market is driven by increased genetically modified crop production and rising demand for synthetic genes in emerging markets, particularly for crop enhancement. CRISPR/Cas9 technology is often researchers’ top choice for crop development and modification. New York, Oct. 23, 2023 (GLOBE NEWSWIRE) —…

Continue Reading Gene Editing Market to Be Valued USD 36.4 Billion by 2032, North America in the Lead

Intellia (NTLA) Focuses on Developing Gene-Editing Therapies

Intellia Therapeutics, Inc. NTLA is a clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is evaluating its leading in vivo genome-editing candidates — NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE). Earlier this week, the FDA cleared an…

Continue Reading Intellia (NTLA) Focuses on Developing Gene-Editing Therapies

Intellia (NTLA) Focuses on Developing Gene-Editing Therapies – October 23, 2023

Intellia Therapeutics, Inc. (NTLA Quick QuoteNTLA – Free Report) is a clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is evaluating its leading in vivo genome-editing candidates — NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE). Earlier this…

Continue Reading Intellia (NTLA) Focuses on Developing Gene-Editing Therapies – October 23, 2023

Regulatory-first for gene editing therapy

The world’s first investigational in vivo CRISPR-based gene editing therapy cleared for late-stage clinical development is expected to enter Phase III in late 2023. The Investigational New Drug (IND) application for Intellia Therapeutics’ in vivo CRISPR-based candidate NTLA-2001, has been cleared as a gene editing therapy for transthyretin (ATTR) amyloidosis…

Continue Reading Regulatory-first for gene editing therapy

Intellia Therapeutics: FDA Allows To Begin Phase 3 Trial Of NTLA-2001 – Quick Facts

(RTTNews) – Intellia Therapeutics, Inc. (NTLA) announced the FDA has cleared the company’s Investigational New Drug application for NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy. The global Phase 3 study of NTLA-2001, an in vivo CRISPR-based gene editing candidate, is anticipated to initiate by year-end 2023. “The FDA…

Continue Reading Intellia Therapeutics: FDA Allows To Begin Phase 3 Trial Of NTLA-2001 – Quick Facts

Intellia Therapeutics (NTLA) Receives FDA Clearance of IND to Initiate a Phase 3 Trial of NTLA-2001

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy….

Continue Reading Intellia Therapeutics (NTLA) Receives FDA Clearance of IND to Initiate a Phase 3 Trial of NTLA-2001

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy -October 18, 2023 at 07:00 am EDT

Intellia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the company?s Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy. The global Phase 3 study of NTLA-2001, an in vivo CRISPR-based gene editing candidate, is expected to initiate…

Continue Reading Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy -October 18, 2023 at 07:00 am EDT

EMA grants PRIME designation to NTLA-2002 gene-editing therapy | Hereditary angioedema treatment has begun dosing in a Phase 2 trial

The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to Intellia Therapeutics’ NTLA-2002, an experimental gene-editing therapy to prevent swelling attacks in people with hereditary angioedema (HAE). A PRIME designation supports the development of experimental therapies that address unmet medical needs. Eligibility for this status is based on…

Continue Reading EMA grants PRIME designation to NTLA-2002 gene-editing therapy | Hereditary angioedema treatment has begun dosing in a Phase 2 trial

2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years

This year has been a tale of two markets for growth stocks. Large-cap growth companies with exposure to either artificial intelligence (AI) or weight-loss products have posted enormous returns for shareholders in 2023. Small- to mid-cap growth stocks, on the other hand, have softened in the face of rising interest…

Continue Reading 2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years

Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran (NASDAQ:ALNY)

Cardiac amyloidosis OGphoto Alnylam logo We rate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is based on the high probability of success for Vutrisiran, the company’s next-generation inverse RNA or RNAi candidate, in treating cardiac amyloidosis in…

Continue Reading Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran (NASDAQ:ALNY)

Intellia Therapeutics Receives Priority Medicines (PRIME)

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE)….

Continue Reading Intellia Therapeutics Receives Priority Medicines (PRIME)

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of…

Continue Reading Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

FDA Rejection Is a Delay, Not a Detour for Alnylam’s Aim to Treat Heart Disorder

An Alnylam Pharmaceuticals drug developed to treat a rare disease’s potentially fatal effects on the heart has fallen short in its bid for FDA approval, costing the company a chance to immediately challenge a Pfizer product that has become a blockbuster seller in the indication. But the biotech still has…

Continue Reading FDA Rejection Is a Delay, Not a Detour for Alnylam’s Aim to Treat Heart Disorder

Analysts Weigh in on Healthcare Giants Amgen and Intellia Therapeutics

According to analysts, Evan Seigerman of BMO Capital has maintained a Hold rating on Amgen (AMGN) with a price target of $260.00. Seigerman, a 4-star analyst, has an average return of 5.3% and a 44.2% success rate. Seigerman focuses on stocks in the Healthcare sector, including Structure Therapeutics, Vertex Pharmaceuticals,…

Continue Reading Analysts Weigh in on Healthcare Giants Amgen and Intellia Therapeutics

Regeneron, Intellia Expand CRISPR Pact to Neurological and Muscular Diseases

Pictured: Illustration of a CRISPR-Cas9 system conducting edits on a DNA strand/iStock, Meletios Verras Regeneron on Tuesday announced it is expanding an existing collaboration agreement with Intellia Therapeutics to develop CRISPR-based gene editing therapies targeting neurological and muscular diseases. The expanded agreement will combine Regeneron’s proprietary delivery systems and antibody-targeted adeno-associated…

Continue Reading Regeneron, Intellia Expand CRISPR Pact to Neurological and Muscular Diseases

Regeneron, Intellia expand CRISPR-based research effort

Regenereon and Intellia Therapeutics expanded a long-running research pact to develop additional CRISPR-based gene editing therapies focused on neurological and muscular diseases. Terms call for the companies to research two in vivo non-liver targets, according to a company press release issued Tuesday. Intellia will lead the design of the editing methodology…

Continue Reading Regeneron, Intellia expand CRISPR-based research effort

Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies

Intellia Therapeutics NTLA announced that it has expanded its existing collaboration with Regeneron Pharmaceuticals, Inc. REGN to develop additional in vivo CRISPR-based gene-editing therapies focused on neurological and muscular diseases. Under the expanded collaboration, Regeneron will supply its proprietary antibody-targeted adeno-associated virus vectors and delivery systems, while Intellia will bring its proprietary Nme2…

Continue Reading Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies

REGENERON AND INTELLIA ANNOUNCE EXPANDED RESEARCH COLLABORATION TO DEVELOP CRISPR-BASED THERAPIES FOR THE TREATMENT OF NEUROLOGICAL AND MUSCULAR DISEASES

Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research…

Continue Reading REGENERON AND INTELLIA ANNOUNCE EXPANDED RESEARCH COLLABORATION TO DEVELOP CRISPR-BASED THERAPIES FOR THE TREATMENT OF NEUROLOGICAL AND MUSCULAR DISEASES

Regeneron and Intellia Announce Expanded Research

Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)…

Continue Reading Regeneron and Intellia Announce Expanded Research

7 Top Gene-Editing Stocks to Buy | Investing

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and can often take the form of adding a functioning copy of a gene. Gene editing takes the science to the…

Continue Reading 7 Top Gene-Editing Stocks to Buy | Investing

3 Top Gene-Editing Stocks with Long-Term Potential

The global gene-editing market is projected to skyrocket from US$5 billion in 2021 to US$21.4 billion in 2030, growing 17.3% annually. The increasing prevalence of genetic disorders, leading to a range of diseases, is fuelling demand for personalized medicine and is the driving force behind the sharp rise of the…

Continue Reading 3 Top Gene-Editing Stocks with Long-Term Potential

How Can CRISPR Be Used to Treat Cancer

CRISPR Beyond Genetic Diseases When CRISPR-Cas9 was first found, and subsequently earned its discoverers a Nobel Price in 2020, the obvious first application of this technology was gene therapy. This is because CRISPR allows for very precise and targeted gene editing, making possible the idea of correcting abnormal gene sequence…

Continue Reading How Can CRISPR Be Used to Treat Cancer

Cathie Wood Loads Up on These 2 Innovation Stocks

Perceived wisdom goes that the way to outperform the market this year has been by leaning into the Magnificent Seven stocks (AAPL, AMZN, GOOGL, META, MSFT, NVDA, TSLA). These market leaders – all tech giants – are seen as being responsible for the market’s rally, but hold that thought, says…

Continue Reading Cathie Wood Loads Up on These 2 Innovation Stocks

Assessing Analyst Ratings and Institutional Holdings: A Comprehensive Look at Intellia Therapeutics

In-Depth Analysis of Intellia Therapeutics: Recent Analyst Ratings and Institutional Holdings August 10, 2023 Intellia Therapeutics (NASDAQ: NTLA), a leading biotechnology company specializing in CRISPR/Cas9 gene editing technology, has recently been the subject of much scrutiny from research analysts. In this article, we will delve into the various analyst ratings…

Continue Reading Assessing Analyst Ratings and Institutional Holdings: A Comprehensive Look at Intellia Therapeutics

Phase 3 trial of NTLA-2002 gene-editing therapy for HAE slated for 2024

Enrollment for the Phase 2 portion of a clinical trial testing NTLA-2002, Intellia Therapeutics’ experimental gene-editing therapy for hereditary angioedema (HAE), is expected to be completed this year. This is the result of “substantial interest from physicians and patients to participate in the NTLA-2002 clinical program,” the company stated in…

Continue Reading Phase 3 trial of NTLA-2002 gene-editing therapy for HAE slated for 2024

Understanding the Revolutionary Gene Editing Technology of Intellia Therapeutics Inc. (NASDAQ:NTLA)

Intellia Therapeutics Inc. (NASDAQ:NTLA) is a leading biotechnology company that has garnered attention for its groundbreaking work in the field of gene editing. Utilizing a revolutionary technology known as CRISPR-Cas9, Intellia is at the forefront of a scientific revolution that has the potential to transform the way we treat…

Continue Reading Understanding the Revolutionary Gene Editing Technology of Intellia Therapeutics Inc. (NASDAQ:NTLA)

Citigroup Analyst Adjusts Price Target for Intellia Therapeutics but Varying Forecasts Highlight the Importance of Multiple Perspectives

On August 4, 2023, David Lewis, an analyst at Citigroup, expressed his opinion on Intellia Therapeutics. He maintained a Neutral rating on the company but adjusted the price target from $44 to $40. This suggests that Citigroup anticipates the stock to perform in line with the market and expects the…

Continue Reading Citigroup Analyst Adjusts Price Target for Intellia Therapeutics but Varying Forecasts Highlight the Importance of Multiple Perspectives

CRISPR on the Cusp: The Promise and the Pain Points

Pictured: CRISPR-Cas9 genome editing enzyme/iStock, Artur Plawgo Hereditary angioedema patients treated with Intellia’s NTLA-2002—an in vivo CRISPR-Cas9 therapy— had an average 95% reduction in the sudden, debilitating bouts of swelling that are a hallmark of the disease, with some patients remaining attack-free for more than a year, according to updated Phase…

Continue Reading CRISPR on the Cusp: The Promise and the Pain Points

1 Cathie Wood Stock That Could Double Your Money

Cathie Wood’s Ark Investment Management has deemed CRISPR/Cas 9 genome editing as “biotech’s breakthrough of the century.” Back in 2018, Ark identified this gene-editing tool as a potential $2 trillion-a-year opportunity, thanks to its potential to disrupt the treatment of 10,000 monogenic human diseases, aquaculture, and medical diagnostics. After a…

Continue Reading 1 Cathie Wood Stock That Could Double Your Money

Axsome Therapeutics at the Forefront of Innovative ADHD Treatments FOCUS Phase 3 Trial and Promising Results

On July 7, 2023, Axsome Therapeutics embarked on the groundbreaking FOCUS Phase 3 trial to investigate the potential of Solriamfetol as a treatment for Attention Deficit Hyperactivity Disorder (ADHD) in adults. This trial is designed to be randomized, double-blind, and placebo-controlled, ensuring rigorous evaluation of the efficacy and safety of…

Continue Reading Axsome Therapeutics at the Forefront of Innovative ADHD Treatments FOCUS Phase 3 Trial and Promising Results

Pfizer Bets on Caribou’s Gene-Edited Cancer Treatment

Text size Caribou is one of several public companies testing medical treatments based on the gene-editing technique called Crispr. Dreamstime Investors were excited about Caribou Biosciences when the gene-editing company came public in 2021. As enthusiasm waned for genetic medicine start-ups, Caribou stock sank from above $30 to a recent…

Continue Reading Pfizer Bets on Caribou’s Gene-Edited Cancer Treatment

Trends in next-generation delivery technologies to advance gene-modified cell therapies

The potential for breakthrough cell and gene therapies to transform healthcare cannot be underestimated. Some of the most complex and sophisticated medical treatments in development involve reprogramming a patient’s immune system to fight and even prevent the development of diseases, which are either difficult to treat or untreatable using traditional…

Continue Reading Trends in next-generation delivery technologies to advance gene-modified cell therapies

Scientists Baffled as Men Overcome “Incurable” Heart Failure

Three elderly men diagnosed with an until-now irreversible heart condition, transthyretin cardiac amyloidosis, experienced an unprecedented spontaneous recovery confirmed by medical scans, leading researchers at UCL and the Royal Free Hospital to identify a unique amyloid-targeting immune response in these patients. This breakthrough raises the potential for new treatments and…

Continue Reading Scientists Baffled as Men Overcome “Incurable” Heart Failure

Insider Sell: Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its…

Continue Reading Insider Sell: Intellia Therapeutics

Gene Editing Is Working. Wall Street Is Taking Notice.

Text size Other gene editors pursuing sickle cell include Beam Therapeutics. Dreamstime Gene-editing stocks are regaining favor on Wall Street this year as evidence builds for their treatments of deadly diseases such as sickle cell. Shares of Crispr Therapeutics (ticker: CRSP) are up 45% this year, compared with the Nasdaq…

Continue Reading Gene Editing Is Working. Wall Street Is Taking Notice.

9 of 10 HAE patients free of attacks with gene-editing therapy, NTLA-2002 | Phase 1/2 trial enrolling new hereditary angioedema group

Over the months after a single treatment with the experimental gene-editing therapy NTLA-2002, nine of 10 people with hereditary angioedema (HAE) in a Phase 1/2 trial have been free from swelling attacks. Three patients with high pretreatment attack rates, ranging from 4.4 to 16.8 each month, have gone without an…

Continue Reading 9 of 10 HAE patients free of attacks with gene-editing therapy, NTLA-2002 | Phase 1/2 trial enrolling new hereditary angioedema group

10 DNA Stocks Billionaires Are Loading Up On

In this article, we discuss 10 DNA stocks that billionaires love. If you want to skip our detailed analysis of the DNA market, head over to 5 DNA Stocks Billionaires Are Loading Up On.  Genomics is the study of a complete set of DNA within an organism. The global genomics…

Continue Reading 10 DNA Stocks Billionaires Are Loading Up On

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

CAMBRIDGE – Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced updated interim results from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002. NTLA-2002 is an in vivo, systemically administered CRISPR candidate being…

Continue Reading Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

Intellia Therapeutics reveals promising Phase I data for HAE

Intellia Therapeutics has revealed interim data from the first portion of its Phase I/II study (NCT05120830) showing its investigational drug, NTLA-2002, could become a functional cure for people living with hereditary angioedema (HAE). The results, unveiled at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023 (being…

Continue Reading Intellia Therapeutics reveals promising Phase I data for HAE

Neuberger Berman Group LLC lowers its position in Intellia Therapeutics by 22.4%: What it could mean for future investments.

On the heels of its most recent Form 13F filing with the Securities and Exchange Commission, Neuberger Berman Group LLC has lowered its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by a staggering 22.4%. The financial management firm’s decision to sell off 31,325 shares left it with a more limited stock…

Continue Reading Neuberger Berman Group LLC lowers its position in Intellia Therapeutics by 22.4%: What it could mean for future investments.

Intellia Therapeutics Announces New Positive Clinical Data

Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE) Across all patients (n=10), a single dose of NTLA-2002 led to a 95% mean reduction in monthly HAE attack rate through the latest follow-up All patients who achieved greater…

Continue Reading Intellia Therapeutics Announces New Positive Clinical Data

Can This Gene-Editing Stock Deliver 10X Returns?

Not many stocks are truly capable of generating a 1,000% return on investment within a reasonable time frame. Even so, a fair number of next-generation technology stocks have hit this lofty milestone over the years. In almost every case, the market woefully underestimated the company’s core value proposition ahead of…

Continue Reading Can This Gene-Editing Stock Deliver 10X Returns?

Astonishing new research shows heart condition can be reversed | News | News & Media

7 June 2023 Three men who had heart failure caused by the build-up of sticky, toxic proteins are now free of symptoms after their condition spontaneously reversed in an unprecedented case described by a team at UCL and the Royal Free Hospital.  The condition, a form of amyloidosis affecting the…

Continue Reading Astonishing new research shows heart condition can be reversed | News | News & Media

One and Done? How CRISPR Is Changing the Clinical Outlook for Multiple Diseases

Credit: SERGII IAREMENKO / Getty Images A little over a decade ago, a paper was published in Science1  that made science fiction a reality. Emmanuel Charpentier, Jennifer Doudna, and colleagues reported that they had identified a means of harnessing an element of a bacterial immune system to carry out genome…

Continue Reading One and Done? How CRISPR Is Changing the Clinical Outlook for Multiple Diseases

Intellia Therapeutics to Present Updated Interim Data from

Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the study Intellia to host investor webcast on Monday, June 12, at 8 a.m. ET CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a…

Continue Reading Intellia Therapeutics to Present Updated Interim Data from

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023 Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the…

Continue Reading Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

Intellia Therapeutics Sees Decrease in Short Interest as Institutional Investors Change Positions

Intellia Therapeutics, Inc., a clinical stage genome editing company, has seen a significant decrease in its short interest during the month of May. The short interest totalled 5,940,000 shares as of May 15th. This is a decrease of approximately 13% from the April 30th total of 6,830,000 shares. With an…

Continue Reading Intellia Therapeutics Sees Decrease in Short Interest as Institutional Investors Change Positions

Intellia Therapeutics: Pioneering Gene Editing Technology with Potential for Medical Breakthroughs

May 26, 2023 marks an important milestone for Intellia Therapeutics, Inc. (NASDAQ:NTLA), a biotechnology company that specializes in developing treatments using gene editing technology CRISPR/Cas9. The company’s latest earnings report had investors cautiously optimistic about the potential success of its pipeline of therapies. Notably, UBS Group AG also made headlines…

Continue Reading Intellia Therapeutics: Pioneering Gene Editing Technology with Potential for Medical Breakthroughs

Is it Time to Dump Intellia Therapeutics Inc (NTLA) Stock After it Has Fallen 0.93% in a Week?

News Home Tuesday, May 16, 2023 12:47 PM | InvestorsObserver Analysts Mentioned in this article The market has been high on Intellia Therapeutics Inc (NTLA) stock recently. NTLA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Intellia Therapeutics Inc has a Bullish sentiment reading. Find out what this means…

Continue Reading Is it Time to Dump Intellia Therapeutics Inc (NTLA) Stock After it Has Fallen 0.93% in a Week?

CRISPR Therapies Pipeline, Clinical Trials Analysis, FDA Approvals, and Emerging Drugs 2023 | Major Companies

PRESS RELEASE Published May 17, 2023 DelveInsight’s, “CRISPR Therapies Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including CRISPR Therapies clinical trials and nonclinical stage products. It also covers the therapeutics…

Continue Reading CRISPR Therapies Pipeline, Clinical Trials Analysis, FDA Approvals, and Emerging Drugs 2023 | Major Companies

Intellia Therapeutics Emerges as a Major Player in the Lucrative Biotech Industry

The world is advancing at an unprecedented pace, with breakthrough technologies and innovations emerging to cater to the changing demands of consumers. One such sector that has caught the eye of investors and experts alike is the field of biotechnology. Among this highly lucrative sector, Intellia Therapeutics, Inc. (NASDAQ:NTLA) has…

Continue Reading Intellia Therapeutics Emerges as a Major Player in the Lucrative Biotech Industry

FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

PRESS RELEASE Published May 11, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, CRISPR Therapies pipeline constitutes 25+ key companies continuously working towards developing 30+ CRISPR Therapies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The CRISPR Therapies…

Continue Reading FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

Intellia Therapeutics’ Transformative Approach to Medical Treatment Sends Shockwaves Through the Healthcare Industry

Intellia Therapeutics’ last quarterly earnings results were a testament to the company’s transformative approach towards medical treatment. The clinical stage genome editing firm, which uses the CRISPR/Cas9 system to develop curative therapeutics, reported impressive numbers that exceeded analyst expectations. Intellia Therapeutics posted an EPS of ($1.17) for the quarter, beating…

Continue Reading Intellia Therapeutics’ Transformative Approach to Medical Treatment Sends Shockwaves Through the Healthcare Industry

Gene editing: overhyped or unstoppable tide?

Only 10 years since Crispr made a splash as a possible therapeutic approach, the first product using Crispr/Cas9 gene editing is on the verge of approval. Vertex and Crispr Therapeutics’ exa-cel, for sickle cell anaemia and beta thalassaemia, has been filed with US and European regulators. Alongside this breakneck speed…

Continue Reading Gene editing: overhyped or unstoppable tide?

Investment Firm Moors & Cabot Inc Acquires Stake in Genome Editing Company Intellia Therapeutics (NASDAQ:NTLA)

The ever-evolving world of medicine and biotechnology continues to grow every day. Such growth attracts investors seeking a piece of the pie, which leads to acquisition acts like the one we saw from &Moors & Cabot Inc. According to the Securities and Exchange Commission (SEC) recent filing by Moors &…

Continue Reading Investment Firm Moors & Cabot Inc Acquires Stake in Genome Editing Company Intellia Therapeutics (NASDAQ:NTLA)

INTELLIA THERAPEUTICS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)

Forward-looking Information This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be…

Continue Reading INTELLIA THERAPEUTICS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today released its 2023 Corporate Responsibility report. The report provides a comprehensive update of the Company’s performance and progress across key Environmental, Social…

Continue Reading Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

Intellia Therapeutics: Leading the Way in Revolutionary Genome Editing Techniques

Intellia Therapeutics: Revolutionary Genome Editing Techniques Intellia Therapeutics (NASDAQ:NTLA), the clinical stage genome editing company, is all set to release its quarterly earnings data before the market opens on Thursday, May 4th. This Boston-based biotech firm engages in developing curative therapeutics that fix disease-associated genes with a single treatment. What…

Continue Reading Intellia Therapeutics: Leading the Way in Revolutionary Genome Editing Techniques

The 3 Most Promising Gene Editing Stocks to Buy in 2023

Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring radical changes to life as we know it. That’s why CRISPR stocks that can edit genes have…

Continue Reading The 3 Most Promising Gene Editing Stocks to Buy in 2023

ProShare Advisors LLC Increases Holdings in Intellia Therapeutics, Inc. by 17.7% in Q4 Fiscal Year

Institutional investor ProShare Advisors LLC has announced that it has increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 17.7% in the fourth quarter of the most recent fiscal year. According to the company’s latest filing with the Securities and Exchange Commission, ProShare Advisors now owns 18,735 shares of Intellia…

Continue Reading ProShare Advisors LLC Increases Holdings in Intellia Therapeutics, Inc. by 17.7% in Q4 Fiscal Year

12 Gene Editing Stocks With the Best Long-Term Potential

In this article, we will take a look at the 12 gene editing stocks with the best long-term potential. To see more such companies, go directly to 5 Gene Editing Stocks With the Best Long-Term Potential. Gene editing stocks are gaining ground on the back of an upbeat tone in…

Continue Reading 12 Gene Editing Stocks With the Best Long-Term Potential

Intellia Therapeutics: At the Forefront of Gene Therapy Revolution, Analysts Optimistic Despite Mixed Responses

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been the subject of intense scrutiny by the financial analysts and market investors alike. The company, which is at the forefront of developing gene therapy treatments for genetic disorders using CRISPR/Cas9 technology, has garnered a consensus rating of “Moderate Buy” from twenty analysts as reported…

Continue Reading Intellia Therapeutics: At the Forefront of Gene Therapy Revolution, Analysts Optimistic Despite Mixed Responses

Top 10 CRISPR Stocks To Buy

In this article, we discuss the top 10 CRISPR stocks to buy. If you want to see more stocks in this selection, check out Top 5 CRISPR Stocks To Buy.  Molecular biology, genetics, and genomics are in a significant period in history where technical capabilities and methods enable the editing…

Continue Reading Top 10 CRISPR Stocks To Buy

Intellia Therapeutics Names Bill Chase to its Board of Directors

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the appointment of Bill Chase, MBA, to its board of directors. Mr. Chase will be a member of…

Continue Reading Intellia Therapeutics Names Bill Chase to its Board of Directors

25+ Active Companies working to develop 30+ Pipeline Therapies for CRISPR Therapies Treatment Landscape

PRESS RELEASE Published April 12, 2023 DelveInsight’s, “CRISPR Therapies Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including CRISPR Therapies clinical trials and nonclinical stage products. It also covers the therapeutics…

Continue Reading 25+ Active Companies working to develop 30+ Pipeline Therapies for CRISPR Therapies Treatment Landscape

Gratus Capital LLC Acquires Intellia Therapeutics to Enhance Investment Opportunities

Gratus Capital LLC, a renowned hedge fund management firm, added to its impressive portfolio by announcing the acquisition of Intellia Therapeutics in a recent Form 13F filing with the Securities and Exchange Commission (SEC). According to the report, Gratus Capital purchased 67,311 shares of the company’s stock valued at approximately…

Continue Reading Gratus Capital LLC Acquires Intellia Therapeutics to Enhance Investment Opportunities

Gene Editing Therapeutics Could Hit the Market in 2023

Pictured: Illustration of CRISPR-Cas9 editing DNA / iStock, Artur Plawgo Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials. As these programs mature, 2023 could be a pivotal year for companies…

Continue Reading Gene Editing Therapeutics Could Hit the Market in 2023

Intellia Seeks to Broaden Gene Editing’s Potential with Full-Spectrum Approach

Pictured: Intellia office building with logo/company courtesy With several recent milestones, Intellia Therapeutics is setting a solid foundation for gene editing in rare diseases like hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis with an eye toward broader patient populations. Laura Sepp-Lorenzino, Ph.D., EVP and chief scientific officer, joined Intellia in…

Continue Reading Intellia Seeks to Broaden Gene Editing’s Potential with Full-Spectrum Approach

First CRISPR therapy seeks landmark approval

Credit: S. Harris/Springer Nature Limited Vertex and CRISPR Therapeutics have submitted their CRISPR-based ex vivo cell therapy exagamglogene autotemcel (exa-cel) for FDA approval, for sickle cell disease (SCD) and beta-thalassemia. A regulatory decision on the gene-editing candidate is expected within 8 to 12 months. The companies have also filed for…

Continue Reading First CRISPR therapy seeks landmark approval

CRISPR & Cas Genes Market Will Registered 17.03% Growth Globally

The CRISPR & Cas Genes market growth is driven by increasing number of clinical trials associates with CRIPR technology and rising of development of novel technologies. The CRISPR & Cas genes market revenue will reach at USD 8.96 billion by 2030 with a CAGR of around 17.03% from 2022 to…

Continue Reading CRISPR & Cas Genes Market Will Registered 17.03% Growth Globally

Intellia Therapeutics: A Leader in CRISPR/Cas9 Genome Editing and Emerging Medical Technologies

Intellia Therapeutics (NASDAQ:NTLA) has recently received a rating downgrade by JPMorgan Chase & Co. The equities research firm reduced the price target of the company from $82.00 to $79.00. The current rating on this stock is “overweight,” indicating that it presents a favorable investment opportunity. The new price target predicts…

Continue Reading Intellia Therapeutics: A Leader in CRISPR/Cas9 Genome Editing and Emerging Medical Technologies

Brokerages have given Intellia Therapeutics, Inc. (NASDAQ:NTLA) an average rating of “Moderate Buy.”

The nineteen analysts currently following Intellia Therapeutics, INC (NASDAQ: NTLA) have reportedly given the company’s shares a rating of “Moderate Buy” as the consensus recommendation for the investment strategy, as reported by Bloomberg.com. Investment professionals have made six recommendations regarding the stock: three to buy the stock, four to hold…

Continue Reading Brokerages have given Intellia Therapeutics, Inc. (NASDAQ:NTLA) an average rating of “Moderate Buy.”

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) —Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2002 for the treatment…

Continue Reading Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002

Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today?

Amid yet another soft session on Wall Street, biotechnology firm Intellia Therapeutics (NASDAQ:NTLA) brightened the room considerably. Receiving a regulatory green light from the Food and Drug Administration (FDA), Intellia can now begin testing its CRISPR gene-editing technology in human patients. Naturally, NTLA stock jumped on the implications, initially popping…

Continue Reading Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today?

FDA clears Intellia to start US tests of ‘in vivo’ gene editing drug

The Food and Drug Administration has cleared Intellia Therapeutics to start human testing in the U.S. of an experimental CRISPR medicine for a rare swelling disorder, a sign the agency could be getting more comfortable with medicines that edit genes inside the body. Intellia on Thursday said the FDA will…

Continue Reading FDA clears Intellia to start US tests of ‘in vivo’ gene editing drug

What is the Market’s View on Intellia Therapeutics Inc (NTLA) Stock’s Price and Volume Trends Thursday?

News Home Thursday, March 02, 2023 11:23 AM | InvestorsObserver Analysts Mentioned in this article The market has been high on Intellia Therapeutics Inc (NTLA) stock recently. NTLA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Intellia Therapeutics Inc has a Bullish sentiment reading. Find out what this means…

Continue Reading What is the Market’s View on Intellia Therapeutics Inc (NTLA) Stock’s Price and Volume Trends Thursday?

Crispr Therapeutics: I Sense A Long Bull Run As First Approval Approaches (NASDAQ:CRSP)

alberto clemares expósito/iStock via Getty Images Investment Overview – Investors Struggle To Make Up Their Minds on Crispr Despite Sickle Cell Disease Approval Progress Studying the share price performance of Crispr Therapeutics (NASDAQ:CRSP) during the past five years, one thing seems clear – investors and the market can’t make up…

Continue Reading Crispr Therapeutics: I Sense A Long Bull Run As First Approval Approaches (NASDAQ:CRSP)

INTELLIA THERAPEUTICS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)

Our management’s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements included in this Annual Report on Form 10-K, which have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and…

Continue Reading INTELLIA THERAPEUTICS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)

2 High-Risk, High-Reward Stock Bets Cathie Wood Is Taking Into 2023

The tech-heavy Nasdaq represents a collection of more risky stocks than the other major indexes and that is reflected by a poorer performance in bear markets and a better display during bull runs. But the risks associated with the Nasdaq are mere child play compared to edgier funds such as…

Continue Reading 2 High-Risk, High-Reward Stock Bets Cathie Wood Is Taking Into 2023

EDIT stock, BEAM stock win bullish views in Cantor gene editing coverage (NASDAQ:EDIT)

Natali_Mis Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA), and Beam Therapeutics (NASDAQ:BEAM) were among clinical-stage biotechs to receive Overweight ratings at Cantor Fitzgerald as the firm launched its coverage on several gene editing companies. The analyst Rick Bienkowski sees multiple catalysts for gene editing companies at a time when the subsector…

Continue Reading EDIT stock, BEAM stock win bullish views in Cantor gene editing coverage (NASDAQ:EDIT)

The Texas Teacher Retirement System increases its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

According to the most recent filing that the company made with the SEC, the Teacher Retirement System of Texas increased its holdings in Intellia Therapeutics, Inc. (NASDAQ: NTLA) during the third quarter by 107.4 percentage points. As a result of the fund’s purchase of an additional 11,534 shares of the…

Continue Reading The Texas Teacher Retirement System increases its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

SVB Leerink Brokers Lower Earnings Estimates for Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) – Equities research analysts at SVB Leerink dropped their FY2022 earnings per share estimates for shares of Intellia Therapeutics in a research note issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar now anticipates that the company will earn ($5.72) per share…

Continue Reading SVB Leerink Brokers Lower Earnings Estimates for Intellia Therapeutics, Inc. (NASDAQ:NTLA)

6 Undervalued Biotech Stocks for 2023

In the face of the bear market, biotechnology stocks have been performing better than the broader market, but Morningstar analysts say there are still plenty of undervalued stocks in this dynamic industry. That includes big names such as Moderna MRNA, which was in the spotlight for its coronavirus vaccine, and…

Continue Reading 6 Undervalued Biotech Stocks for 2023

3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later

InvestorPlace – Stock Market News, Stock Advice & Trading Tips To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases…

Continue Reading 3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later

3 Gene Editing Stocks With the Best Long-Term Potential

Source: vxhal/ShutterStock.com Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By introducing genetic material into cells, scientists can correct genetic abnormalities in…

Continue Reading 3 Gene Editing Stocks With the Best Long-Term Potential